Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Global gains from high yield corporates


Bookmark and Share
by Paul Tracy, editor High-Yield International

Paul TracyAllianceBernstein Global High Income Fund (AWF) is a closed-end fund that invests primarily in high-yield corporate bonds and, to a lesser extent, emerging market sovereign debt.

High-yield debt consists of bonds issued by companies or governments that are rated below investment grade by the major credit ratings agencies such as Standard & Poor's and Moody's.

Roughly two-thirds of the fund's holdings are rated below investment grade, and the average coupon rate of the fund's bond holdings is just over 8.5%.

Companies and governments rated below investment grade carry higher credit risk, meaning that the odds they'll be unable to repay their borrowings are theoretically higher than for a company carrying an investment-grade credit rating.

Since the risk of default is higher, high-yield bonds tend to carry higher interest rates than investment-grade debt, a means of compensating investors for the extra risk they're taking.
Advertisement
Banner


With rates in the investment grade corporate and government bond markets so low, investors have been looking for higher-yielding alternatives, including high-yield debt. That's powered a significant rally in the exact sort of bonds that AWF focuses on.

For example, the fund's largest holding is a bond issued by the Argentinean government that matures in October 2015 that currently yields around 9%. Argentina has a credit rating of "B" from Standard & Poor's and "B3" from Moody's, several steps below investment grade.

There's no doubt the country has its share of economic and political problems. But Argentina's sovereign debt has seen a significant rally since August as investors are attracted to its high yields and solid economic fundamentals.

AWF's second-largest holding is a series of corporate bonds issued by Russian Agricultural Bank that are rated "BBB", the lowest possible investment-grade credit rating.

While banks in the U.S. and Europe have been troubled in recent years by bad loans made to residential homebuyers and shaky E.U. countries, Russian banks have relatively clean balance sheets.

Russia is a major exporter of natural gas, oil, coal and other commodities and continues to benefit from strong demand and pricing for its natural resources.

And the fund has little exposure whatsoever to debt issued by corporates or governments in fiscally challenged E.U. nations. Only around 0.5% of the fund's total portfolio is invested in bonds issued by Italian firms.

AWF pays a $0.10 monthly distribution, equivalent to a yield of roughly 8.4% at current prices.

Action to Take --> With a well-diversified portfolio of high-yield bonds offering a yield over 8%, AllianceBernstein Global High Income Fund is a solid buy candidate with moderate risk.

Learn more about this financial newsletter at Paul Tracy's High-Yield International.

Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary